药品：Synagis(帕利珠单抗) 公司：阿斯利康
基于106个网页-相关网页
对感染性疾病治疗应用，目前仅 有针对呼吸道合胞病毒（RSV）的人源化单抗（Synagis），已获准用于治疗支气管肺 发育不良的早产儿与婴儿。
基于24个网页-相关网页
• Synagis（单克隆抗体） 主要产品：
基于1个网页-相关网页
Synagis, Porges says, could still have more room for growth on price increases and population growth.
FORBES: Is There Hidden Value In MedImmune?
The all-cash offer for MedImmune gives AstraZeneca the rights to Synagis, a preventive for respiratory infections in premature infants, and a follow-up drug that is still in development.
FORBES: Magazine Article
应用推荐
模块上移
模块下移
不移动